COVID-19 Vaccine and Ovarian Reserve

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04748172

Recruitment Status : Recruiting

First Posted : February 10, 2021

Last Update Posted : March 26, 2021

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Dr. Aya Mohr-Sasson, Sheba Medical Center

Study Description

Brief Summary:

As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .

Condition or disease	Intervention/treatment
Fertility Issues Vaccine Adverse Reaction	Biological: SARS-CoV-2 virus vaccines Diagnostic Test: AMH sampling

Show detailed description

Detailed Description:

Introduction Although there is as yet no scientific evidence that a SARS-CoV-2 virus infection could have negative effects on fertility, currently the possibility that the virus could affect sperm function and egg performance cannot be excluded. Previous studies have already shown an association between influenza and infertility. SARS-CoV-2 seems to be far more aggressive in terms of severe illness, morbidity and mortality in comparison to common influenzas, thus it is reasonable to hypothesize a possible substantial effect of Covid-19 on fertility.

At the cellular level, common influenza viruses promote oxidant-sensitive pathways, leading to increased oxidative stress. This mechanism has been blamed to cause male infertility through a reduction of progressive motility in spermatozoa and a simultaneous increase in sperm DNA fragmentation. Based on this pathogenic pathway, it can be hypothesized that SARS-CoV-2 could increase sperm DNA fragmentation, which might affect fertilizing potential. Along the same lines, SARS-CoV-2 may affect oocyte performance through mechanisms that increase oxidative stress.

As SARS-CoV-2 acts through the angiotensin-converting enzyme 2 (ACE2) receptor, this was proposed as an additional pathway affecting ovaria follicles and oocytes. ACE2 receptors are expressed in human ovaries, while angiotensin has been detected in measurable amounts in the follicular fluid . Therefore, a possible negative impact of the virus through an interaction between the oocyte and the somatic cells cannot be ruled out.

The COVID-19 pandemic exerted tremendous pressure on scientists to develop safe and effective vaccines. A few delivery systems for next-generation vaccines against COVID-19 were introduced. The new-generation vaccines include only a specific antigen or antigens of the pathogen, instead of the whole pathogen, thus providing a better safety profile. While SARS-CoV-2 has four main structural proteins, the spike protein (S) which is located at the outer surface of the virus particles and can bind to ACE2 on the cell surface and causes receptor-mediated endocytosis of the virus, is the main target to evoke the self-immune system.

The mRNA vaccines represent the newest generation of vaccines in which all components can be engineered via chemical synthesis. Due to the mRNA molecules' low apparent transfection efficacy, lipid nanoparticles (LNPs) are often used to incorporate the mRNA molecules for transfection purposes. An additional advantage of the mRNA vaccine is that the antigen expression generated by the mRNA is a transient process and therefore the risk of host DNA integration is negligible. Furthermore, elimination of live materials poses an advantage from a quality control standpoint and allows quick product switching in manufacturing facilities. Since the process is fully-synthetic it also eliminates the risk of disease transmissions from the manufacturing facility. The effect of the systemic generation and introduction of just the S protein of the SARS-CoV-2 could have a negative influence on ovarian follicles and oocytes has not been studied yet.

Anti Mullarian Hormone (AMH) is a glycoprotein produced by the granulosa cells of the antral follicles. Its circulating levels are associated with the fertility state of the ovary and in contrast to other hormones are not influenced by the state of the menstrual cycle. Therefore, AMH levels are considered the measurement of choice for estimating ovarian reserve.

As Israel is the first country to widely vaccinate its population using the mRNA vaccines and due to all the aforementioned, the aim of this study is to evaluate the influence of the mRNA vaccines on ovarian reserve estimated by the change in AMH before and three-month following vaccination.

Material and Methods This is a prospective study including reproductive age women (age 18 to 42) that are planning to be vaccinated in Israel. Women will be asked to sign an informed consent to participate in the study while visiting the ambulatory vaccinating clinics before being vaccinated. Medical information will be collected by the research team during this visit. Women visiting other ambulatory clinics, which are not planning to be vaccinated will be asked to participate as controls. Blood samples will be collected for AMH analysis before administration of the first mRNA vaccine shot and 3 months following the second vaccine shot. An internet questionnaire will be sent following one year from vaccination regarding gynecological and obstetrical outcomes.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	200 participants
Observational Model:	Case-Control
Time Perspective:	Prospective
Official Title:	The Effect of COVID -19 mRNA Vaccine on Ovarian Reserve
Actual Study Start Date :	February 1, 2021
Estimated Primary Completion Date :	February 2022
Estimated Study Completion Date :	February 2022

Groups and Cohorts

Group/Cohort	Intervention/treatment
Study Group: Women who are planning to be vaccinated Women that are planning to be vaccinated, before receiving the first shot of the vaccine	Biological: SARS-CoV-2 virus vaccines mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna) Diagnostic Test: AMH sampling Blood sample for AMH on recruitment and after three months
Control Group: Women who are not planning to be vaccinated Women visiting other ambulatory clinics that are not planning to be vaccinated	Diagnostic Test: AMH sampling Blood sample for AMH on recruitment and after three months

Outcome Measures

Primary Outcome Measures :

Delta in AMH levels [ Time Frame: From first vaccination untill the second AMH sampling - after three month ]
AMA levels on recruitment minos AMH levels after three months

Biospecimen Retention: Samples Without DNA

Blood samples evaluated for Anti Mullarian Hormone (AMH)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 42 Years (Adult)
Sexes Eligible for Study:	Female
Gender Based Eligibility:	Yes
Gender Eligibility Description:	Women in reproductive age
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Reproductive age women (age 18 to 42) that are planning to be vaccinated in Israel

Criteria

Inclusion Criteria:

Age 18-42
No previous exposure to covid-19 vaccine (first or second dose)
No known past Covid-19 infection

Exclusion Criteria:

Premature ovarian failure
Endometriosis
Polycystic ovary syndrome
Pregnancy
Fertility treatment

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04748172

Locations

Layout table for location information

Israel
Sheba Medical Center	Recruiting
Ramat-Gan, Israel, 56506
Contact: Dr. A Mohr-Sasson, M.D 97235302777 ext 97235302777 mohraya@gmail.com
Contact: Aya Mohr- Sasson, M.D 0523692906 mohraya@gmail.com

Sponsors and Collaborators

Sheba Medical Center

More Information

Publications of Results:

Anifandis G, Messini CI, Daponte A, Messinis IE. COVID-19 and fertility: a virtual reality. Reprod Biomed Online. 2020 Aug;41(2):157-159. doi: 10.1016/j.rbmo.2020.05.001. Epub 2020 May 8.

Joguet G, Mansuy JM, Matusali G, Hamdi S, Walschaerts M, Pavili L, Guyomard S, Prisant N, Lamarre P, Dejucq-Rainsford N, Pasquier C, Bujan L. Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study. Lancet Infect Dis. 2017 Nov;17(11):1200-1208. doi: 10.1016/S1473-3099(17)30444-9. Epub 2017 Aug 23.

Percivalle E, Zavattoni M, Fausto F, Rovida F. Zika virus isolation from semen. New Microbiol. 2017 Jul;40(3):197-198. Epub 2017 May 17.

Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox Biology of Respiratory Viral Infections. Viruses. 2018 Jul 26;10(8). pii: E392. doi: 10.3390/v10080392. Review.

Liu M, Chen F, Liu T, Chen F, Liu S, Yang J. The role of oxidative stress in influenza virus infection. Microbes Infect. 2017 Dec;19(12):580-586. doi: 10.1016/j.micinf.2017.08.008. Epub 2017 Sep 14. Review.

Agarwal A, Rana M, Qiu E, AlBunni H, Bui AD, Henkel R. Role of oxidative stress, infection and inflammation in male infertility. Andrologia. 2018 Dec;50(11):e13126. doi: 10.1111/and.13126. Review.

Dutta S, Majzoub A, Agarwal A. Oxidative stress and sperm function: A systematic review on evaluation and management. Arab J Urol. 2019 Apr 24;17(2):87-97. doi: 10.1080/2090598X.2019.1599624. eCollection 2019. Review.

Homa ST, Vassiliou AM, Stone J, Killeen AP, Dawkins A, Xie J, Gould F, Ramsay JWA. A Comparison Between Two Assays for Measuring Seminal Oxidative Stress and their Relationship with Sperm DNA Fragmentation and Semen Parameters. Genes (Basel). 2019 Mar 19;10(3). pii: E236. doi: 10.3390/genes10030236.

Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci. 2004 Nov;61(21):2738-43. Review.

Reis FM, Bouissou DR, Pereira VM, Camargos AF, dos Reis AM, Santos RA. Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fertil Steril. 2011 Jan;95(1):176-81. doi: 10.1016/j.fertnstert.2010.06.060. Epub 2010 Aug 1.

Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech. 2020 Aug 5;21(6):225. doi: 10.1208/s12249-020-01744-7. Review.

Vartak A, Sucheck SJ. Recent Advances in Subunit Vaccine Carriers. Vaccines (Basel). 2016 Apr 19;4(2). pii: E12. doi: 10.3390/vaccines4020012. Review.

Layout table for additonal information

Responsible Party:	Dr. Aya Mohr-Sasson, Principal Investigator, Sheba Medical Center
ClinicalTrials.gov Identifier:	NCT04748172
Other Study ID Numbers:	8121-21-SMC
First Posted:	February 10, 2021 Key Record Dates
Last Update Posted:	March 26, 2021
Last Verified:	February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided
Plan Description:	On request

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Dr. Aya Mohr-Sasson, Sheba Medical Center:


Ovarian reserve Corona-19 virus SARS-CoV-2

Additional relevant MeSH terms:

Layout table for MeSH terms

Infertility

To Top